Position in CADL
as of Mar 31, 2026
· filed Apr 27, 2026
Position Value
$329,500
-$149 QoQ
Shares Held
67,245
+15.3% QoQ
Ownership
0.092%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2024
6 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in CADL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026HB Wealth Management, LLC holds $28,265,702 across 30 Biotechnology names. CADL ranks #16 (1.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | AXSM |
Axsome Therapeutics, Inc.
|
50,237 | $8,491,057 | |
| 2 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
10,287 | $4,593,556 | |
| 3 | REGN |
Regeneron Pharmaceuticals, Inc.
|
3,436 | $2,654,791 | |
| 4 | TECH |
BIO-TECHNE Corp
|
34,140 | $1,784,156 | |
| 5 | EXEL |
Exelixis, Inc.
|
29,055 | $1,246,168 | |
| 6 | SABS |
SAB Biotherapeutics, Inc.
|
307,500 | $1,177,725 | |
| 7 | IMUX |
Immunic, Inc.
|
91,450 | $1,015,095 | |
| 8 | RPRX |
Royalty Pharma plc
|
18,229 | $874,445 |
All Filings in CADL
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $329,500 | 67,245 | Shares | Sole | 2026-04-27 | |
| 2025-12-31 | $329,649 | 58,345 | Shares | Sole | 2026-01-28 | |
| 2025-09-30 | $297,559 | 58,345 | Shares | Sole | 2025-10-23 | |
| 2025-03-31 | $532,795 | 94,300 | Shares | Sole | 2025-05-07 | |
| 2024-12-31 | $757,764 | 87,300 | Shares | Sole | 2025-01-15 | |
| 2024-09-30 | $392,639 | 56,658 | Shares | Sole | 2024-10-15 | |
| No filing history on record for this holder in this stock. | ||||||